Drug updated on 5/17/2024

Dosage FormInjection (intravenous; 50 mg, 100 mg)
Drug ClassTetracycline class antibacterials
Ongoing and
Completed Studies


  • Indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.

Latest News

loading GIF

This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Eravacycline (Xerava) is indicated for the treatment of complicated intra-abdominal infections in patients 18 years and older, with clinical efficacy, microbiological response, and safety profiles comparable to carbapenems.
  • Five studies provided an in-depth comparison of eravacycline to other antibiotics focusing on safety and effectiveness.
  • The studies highlight that eravacycline can be a viable option for infection management in vulnerable populations such as cancer patients where safe treatments are crucial.
  • Among carbapenem-sparing options for treating complicated intra-abdominal infections, eravacycline is positioned as the preferred antibiotic based on P-score rankings considering both adverse events and clinical responses.
  • In randomized controlled trials (RCTs), while there was no significant difference between eravacycline's clinical response or all-cause mortality compared to carbapenems; it did show a higher incidence of adverse events especially nausea without significant differences in serious adverse events or treatment discontinuation.
  • For high-risk subgroups like those with secondary bacteremia concurrent with cIAI, eravacycline maintains its effectiveness showing similar outcomes and eradication rates when compared against comparator carbapenems.

Product Monograph / Prescribing Information

Document TitleYearSource
Xerava (eravacycline) Prescribing Information. 2021Tetraphase Pharmaceuticals Inc, Watertown, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines